OM2 Abbreviated Sensor Verification

NCT ID: NCT06415799

Last Updated: 2025-07-28

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 28 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-02-11
• Study Completion Date: 2024-02-22

Brief Summary

The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.

Detailed Description

To verify the SpO2 and pulse rate accuracy in comparison to reference-standard blood measurements. To achieve paired observations of SpO2 and SaO2 values over the specified SpO2 accuracy range of the prototype pulse oximeter on a group of healthy adult volunteers. The fraction of inspired oxygen (FiO2) delivered to test subjects is varied to achieve a series of targeted steady-state saturation periods. In this study, the investigational pulse oximetry PCBA system saturation measurements will be compared to saturation measurements made by a multi-wavelength CO-oximeter, taken from arterial blood samples from a diverse pool of healthy human subjects.

Conditions

Hypoxia

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Healthy Volunteers

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects 18 to 50 years of age

2. Subject is willing and able to comply with study procedures and duration

3. Subject is willing to sign an informed consent

4. Subject weighs >40kg

5. Subject is a non-smoker or has not smoked within 2 days prior to the study

6. Cleared same day health assessment form and health screening

7. Successful perfusion index ulnar/ulnar+radial ratio test showing adequate collateral blood flow.

Exclusion Criteria

1. Subject is considered as being morbidly obese (defined as BMI >39.5)

2. Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized)

3. Females of childbearing potential who are pregnant, who are trying to get pregnant, or who have a urine test positive for pregnancy on the day of the study

4. Subjects with COHb levels >3% as assessed by CO-Oximetry during the procedure

5. tHb < 10 g/dl as assessed by CO-Oximetry during the procedure

6. MetHb ≥ 2% as assessed by CO-Oximetry during the procedure

7. Subjects with known respiratory conditions such as:

1. uncontrolled / severe asthma

2. flu or influenza type infection

3. pneumonia / bronchitis

4. shortness of breath / respiratory distress

5. unresolved respiratory or lung surgery

6. emphysema, COPD, lung disease

7. recent COVID (last 2 months)

8. Subjects with known heart or cardiovascular conditions such as:

1. hypertension: systolic >140mmHg, or Diastolic >90mmHg on 3 consecutive readings

2. have had cardiovascular surgery

3. chest pain (angina)

4. heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)

5. previous heart attack

6. blocked artery

7. unexplained shortness of breath

8. congestive heart failure (CHF)

9. history of stroke

10. transient ischemic attack

11. carotid artery disease

12. myocardial ischemia

13. myocardial infarction

14. cardiomyopathy

15. implantable active medical device such as pacemaker or automatic defibrillator

9. Self-reported health conditions as identified in the Health Assessment Form

1. diabetes

2. uncontrolled thyroid disease

3. kidney disease / chronic renal impairment

4. history of seizures (except childhood febrile seizures)

5. epilepsy

6. history of unexplained syncope

7. recent history of frequent migraine headaches

8. recent symptomatic head injury, within the last 2 months

9. cancer requiring chemotherapy, radiation, or current treatment

10. subjects with known clotting disorders

11. history of bleeding disorders or personal history of prolonged bleeding from injury

12. history of blood clots

13. hemophilia

14. sickle cell trait or disease

15. current use of blood thinner: prescription or daily use of aspirin

16. subjects with Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors

17. participants with severe allergy to iodine (only applicable if iodine is used)

18. subjects with prior or known severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocain) or heparin

19. arterial cannulation within the last 30 days prior to study date, (this may exclude only one radial artery site, left or right)

20. history of clinically significant complications from previous arterial cannulation

21. unwillingness or inability to remove colored nail polish or colored artificial nails other than clear from test digits

22. other known health condition, upon disclosure in Health Assessment form

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Medtronic - MITG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Monica Rabanal

Role: PRINCIPAL_INVESTIGATOR

Element Labs

Locations

Element

Louisville, Colorado, United States

Countries

United States

Other Identifiers

MDT23027OM2VAB

Identifier Type: -

Identifier Source: org_study_id